| Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? | |
| | |
MedLine Citation:
|
PMID: 18554258 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Sexual dysfunction after breast cancer has been attributed to a variety of treatment associated and psychological factors. Data on the role of a treatment-induced decrease of testosterone for the development of sexual problems in breast cancer survivors have remained inconclusive. However, androgen metabolites constitute a more reliable measure for total androgen activity. AIM: To measure levels of total androgen activity in breast cancer patients and to investigate relevant predictors of sexual dysfunction after breast cancer. METHODS: Twenty-nine patients with a premenopausal diagnosis of Stage I or II breast cancer and terminated adjuvant treatment, completed questionnaires on sexuality, quality of relationship, body image, and depression. In addition, blood samples were taken for the analysis of sex steroids. MAIN OUTCOME MEASURES: Female Sexual Function Index (FSFI), Relationship (PFB), Beck Depression Inventory, and European Organization for Research and Treatment of Cancer quality of life questionnaire. Analysis of dihydroepiandrosterone, dihydroepiandrosterone-sulfate, androstenedione, 17beta-diol, testosterone, dihydrotestosterone, androsterone, and ADT-G, 3-alpha-diol-3G, 3-alpha-diol-17G. RESULTS: Low levels of sex steroids reflected the medication-induced postmenopausal status independent of the type of chemotherapy treatment. Sexual dysfunction was present in 68% of the study group. Women with a history of chemotherapy were more affected in all of the FSFI-domains. The only predictor for desire was quality of relationship, while chemotherapy was predictive for problems with arousal, lubrication, orgasm, and sexual pain. Sexual satisfaction and higher FSFI sum scores were predicted by better quality of relationship and no history of chemotherapy, together explaining 54.2% and 49.7% of the variance. CONCLUSIONS: Sexual dysfunction after breast cancer is common and women should be informed properly at an early stage of treatment. Specific interventions have to be offered considering person-related preexisting factors and couples at risk should be supported in the transition to sexual life after breast cancer. |
| | |
Authors:
|
Judith Alder; Rosanna Zanetti; Edward Wight; Corinne Urech; Nadine Fink; Johannes Bitzer |
Related Documents
:
|
19080028 - A weight loss intervention for african american breast cancer survivors, 2006. 18427948 - Quality of life in cancer patients in south asia: psychometric properties of the sinhal... 20084618 - Positive adjustment to breast cancer: development of a disease-specific measure and com... 18463968 - Efficacy of nyoshinsan/tj-67, a traditional herbal medicine, for menopausal symtoms fol... 6886188 - Chemosurgical reports: perineural spread of basal-cell carcinoma. 8564968 - Mkt-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity i... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-06-28 |
Journal Detail:
|
Title: The journal of sexual medicine Volume: 5 ISSN: 1743-6109 ISO Abbreviation: - Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-09-08 Completed Date: 2008-12-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101230693 Medline TA: J Sex Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1898-906 Citation Subset: IM |
Affiliation:
|
University Hospital Basel, Department Obstetrics and Gynecology, Basel, Switzerland. jalder@uhbs.ch |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Androgens / blood* Androsterone / blood Breast Neoplasms / blood*, drug therapy, pathology Chemotherapy, Adjuvant Combined Modality Therapy Dihydrotestosterone / blood Estradiol / blood Female Humans Libido / physiology Middle Aged Orgasm / physiology Premenopause / blood* Sexual Dysfunction, Physiological / blood*, diagnosis, psychology Testosterone / blood |
| Chemical | |
Reg. No./Substance:
|
0/Androgens; 50-28-2/Estradiol; 521-18-6/Dihydrotestosterone; 53-41-8/Androsterone; 58-22-0/Testosterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The chronology of depression and distress in men with Peyronie's disease.
Next Document: Expression and activity of heme oxygenase-1 in artificially induced low-flow priapism in rat penile ...